Nov 28, 2014:
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update

Nov 4, 2014:
iCo Therapeutics Announces Oral Amphotericin Presentations at AAPS

Oct 22, 2014:
iCo Therapeutics Announces Advancement of Oral Amphotericin B Program

Aug 29, 2014:
iCo Therapeutics Announces Second Quarter 2014 Financial Results

Aug 19, 2014:
iCo Therapeutics Announces Positive Oral Amphotericin B Study Results

Jun 30, 2014:
iCo Therapeutics Announces Director Election Results From Its Annual Meeting of Shareholders

Jun 9, 2014:
iCo Therapeutics Announces Top-Line Primary Endpoint Data from iCo-007 Phase 2 iDEAL Study in Diabetic Macular Edema

May 29, 2014:
iCo Therapeutics Announces First Quarter 2014 Financial Results

Apr 29, 2014:
iCo Therapeutics Announces Poster Presentation at ARVO

Apr 24, 2014:
iCo Therapeutics Announces Year End 2013 Financial Results

Mar 5, 2014:
iCo Therapeutics Announces Final Eight Month Patient Visit in Phase 2 iDEAL Study

Feb 25, 2014:
iCo Therapeutics Announces DTC Approval

Jan 27, 2014:
iCo Therapeutics Inc. Completes C$6.75 Million Equity Financing

Jan 22, 2014:
iCo Therapeutics Inc. Announces C$6.75 Million Equity Financing

Jan 21, 2014:
iCo Therapeutics Inc. Announces Overnight Marketed Equity Offering